Affiliate disclosure: The RX Index earns a commission when you sign up with some of the providers mentioned on this page. It does not affect what you pay, and it never determines our rankings or which providers we cover. Read the full disclosure.
CMS BALANCE Model Zepbound KwikPen: How to Get It for $50 a Month (2026–2027)
Disclosure: Some links on this page are affiliate links. If you purchase through these links, we may earn a commission at no extra cost to you.
Straight answer before you scroll
Yes, eligible Medicare members can get the Zepbound KwikPen for $50 a month — but only the KwikPen, and only through the Medicare GLP-1 Bridge, which runs July 1, 2026 through December 31, 2027. Zepbound vials and single-dose pens are not covered.
You’ll need the right Medicare drug plan, a qualifying BMI or health condition, a prescription, and prior authorization. Miss one of those pieces and the $50 price doesn’t apply.
If you’ve searched CMS BALANCE Model Zepbound KwikPen, the real question isn’t “is this real?” — it is. The real question is: “does it fit me, and what do I do next?” That’s what this page answers, including exactly what to do if you don’t qualify.
Free 60-second walkthrough \u2014 same questions your doctor and pharmacist will ask.
The bottom line, at a glance
| Question | Answer |
|---|---|
| Is the Zepbound KwikPen covered? | Yes — but only the KwikPen |
| What’s not covered? | Zepbound single-dose vials and single-dose pens |
| When does it start? | July 1, 2026 |
| When does it end? | December 31, 2027 |
| What will I pay? | $50 a month, flat, no matter the dose |
| The catch most pages skip | It runs outside normal Medicare drug coverage — the $50 does not count toward your yearly out-of-pocket limit |
| Best first step | Check whether your plan, your diagnosis/BMI, and your Zepbound form all match the rules below |
In KFF’s polling, about 56% of people who use GLP-1 drugs said they were hard to afford — including roughly one in four who called them “very difficult.” A flat $50 is a big deal if you qualify. This page tells you exactly whether you do.
CMS BALANCE Model Zepbound KwikPen: is it really part of the $50 Bridge?
Let’s untangle the names, because they get mixed up constantly.
CMS
The Centers for Medicare & Medicaid Services — the federal agency that runs Medicare and Medicaid.
The BALANCE Model
Stands for “Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth.” CMS’s bigger, longer-term plan to expand GLP-1 coverage for obesity. GLP-1 drugs are a class of medicines — Zepbound, Wegovy, Ozempic, Mounjaro, and others — that affect blood sugar and appetite.
The Medicare GLP-1 Bridge
The short-term program that comes first — a temporary way to get covered while the bigger BALANCE program is sorted out. This is the program that gives you the Zepbound KwikPen for $50 a month.
The part that trips people up
In April 2026, CMS delayed the Medicare drug-plan side of the full BALANCE Model. KFF describes that delay as open-ended. Because of the delay, CMS extended the Bridge so it now runs all the way through December 31, 2027 instead of ending in 2026. The Medicaid side of BALANCE is moving on its own track for states that choose to join.
The four things people keep mixing up
“Zepbound” vs. “Zepbound KwikPen.”
The headline says Zepbound. The fine print says the KwikPen form only. That difference is the single most important detail on this page.
The BALANCE Model vs. the Bridge.
BALANCE is the big future program (now delayed for Medicare drug plans). The Bridge is the smaller one that’s actually starting.
“July 2026” vs. “2027.”
A lot of coverage mentions 2027 because of BALANCE. But your Zepbound KwikPen access through the Bridge starts July 1, 2026.
“Covered” vs. “covered like a normal prescription.”
The $50 Bridge price is real, but it works differently from your usual drug plan — more on that in the costs section.
Full BALANCE vs. Bridge context: CMS BALANCE Model GLP-1 overview → · Why the BALANCE Model was delayed →
Why only the Zepbound KwikPen? (And what to do if you use vials or the single-dose pen)
The honest limitation
If you currently use Zepbound single-dose vials or single-dose pens, those forms do not get the $50 Bridge price. That’s a genuine limitation, and it’s worth naming clearly.
But here’s why it’s usually not the end of the road: the KwikPen contains the same medicine (tirzepatide) as the vial — it’s a different device, not a different drug. If you’re open to it, moving to the KwikPen is usually a quick conversation with your prescriber. And because the program runs on one form, the price stays dead simple: $50 a month, every dose, no surprises.
What is the Zepbound KwikPen, exactly?
A prefilled, multi-dose pen. One pen holds four weekly doses — roughly one month of medicine.
You attach a needle, dial your dose, and inject once a week. No drawing medicine into a syringe.
Single-patient use. Per the FDA label, never share a KwikPen with anyone else, even with a new needle.
Comes in six strengths: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. The 2.5 mg dose is for starting only.
Make sure your prescription says “KwikPen” — and the exact NDC codes
Because the Bridge only covers one form, a prescription that just says “Zepbound” may not be specific enough. Each KwikPen strength has its own NDC (National Drug Code) — the number a pharmacy uses to identify the exact item.
| Zepbound KwikPen strength | NDC (KwikPen) |
|---|---|
| 2.5 mg per dose | 0002-3566-11 |
| 5 mg per dose | 0002-3555-11 |
| 7.5 mg per dose | 0002-3544-11 |
| 10 mg per dose | 0002-3533-11 |
| 12.5 mg per dose | 0002-3522-11 |
| 15 mg per dose | 0002-3511-11 |
Source: LillyDirect / DailyMed. Your prescriber chooses your dose — this table confirms form, not clinical suitability.
Lists exactly what to confirm before your doctor sends the prior-authorization request.
When can you actually get it? Why July 1, 2026 matters more than 2027
| When | What happens |
|---|---|
| Spring 2026 | CMS shares Bridge rules and pharmacy billing details |
| May 2026 | States can start joining the Medicaid side of BALANCE |
| July 1, 2026 | The Medicare GLP-1 Bridge begins — $50 Zepbound KwikPen |
| 2026–2027 | The Bridge runs; the full BALANCE Model for Medicare drug plans stays delayed |
| December 31, 2027 | The Bridge is scheduled to end |
| After 2027 | Unknown — depends on whether CMS launches BALANCE for Medicare drug plans later |
A quick honest note about the future
This is a bridge, not a guarantee. KFF points out there’s no clear path for ongoing Medicare coverage of weight-loss-only GLP-1 use after the Bridge ends, unless the BALANCE Model launches for Medicare drug plans. Treat it as an 18-month window, and watch for news in late 2027.
Is the $50 price for every dose?
Yes. The Bridge copay is $50 a month no matter which KwikPen strength you’re on. With cash prices, higher doses cost more. With the Bridge, the price doesn’t climb as your dose goes up.
Which Medicare plans qualify for the Zepbound KwikPen Bridge?
✓ These plan types can qualify:
- ·Standalone Part D plan
- ·Medicare Advantage with drug coverage (MA-PD): HMO, HMO-POS, local or regional PPO
- ·Special Needs Plans (SNPs)
- ·Employer or union group plans (EGWPs)
- ·Limited Income Newly Eligible Transition (LI NET)
- ·Dual eligible (Medicare + Medicaid) — if plan and rules are met
✗ Not eligible on their own:
- ·Original Medicare with no drug plan
- ·PACE programs (without standalone Part D)
- ·Private fee-for-service (PFFS) plans (without standalone Part D)
- ·Certain Medicare cost plans (without standalone Part D)
Not sure which plan you have? Your plan’s member card and welcome materials will say — or call Medicare at 1-800-MEDICARE (1-800-633-4227).
Who qualifies for the $50 Zepbound KwikPen path?
There are three ways to qualify. You only need to meet one.
| Tier | You may qualify if (at the time GLP-1 treatment started)… |
|---|---|
| Tier 1 | Your BMI was 35 or higher — no other condition needed |
| Tier 2 | Your BMI was 30 or higher and you have HFpEF (heart failure with preserved ejection fraction), high blood pressure that’s still high (over 140/90) even on two blood-pressure medicines, or kidney disease (stage 3a or worse) |
| Tier 3 | Your BMI was 27 or higher and you have prediabetes, a past heart attack, a past stroke, or peripheral artery disease with symptoms (poor blood flow in the limbs) |
Source: CMS Bridge rules. Your doctor confirms which tier fits you. Type 2 diabetes by itself is not on this list — see the sleep apnea section for alternative paths.
Already on a GLP-1? Your starting BMI is what counts
What to gather before your appointment
- 1Your starting BMI — or your height and starting weight so your doctor can calculate it.
- 2Proof of a qualifying condition if you’re using Tier 2 or Tier 3: prediabetes labs, cardiology records for a past heart attack or stroke, blood-pressure readings, or kidney-function tests.
- 3Your current medication list.
- 4Your Medicare drug plan card.
Full eligibility breakdown: Medicare GLP-1 Bridge eligibility guide →
What does it really cost — and the catches no one puts up front
| Path | What you pay for the Zepbound KwikPen |
|---|---|
| Medicare GLP-1 Bridge | $50/month, flat (if eligible) |
| Cash / self-pay (e.g., LillyDirect) | About $299/month to start, up to ~$699/month at higher doses |
| Regular Part D (covered use, e.g., sleep apnea) | Your plan’s normal cost-sharing |
Behind the scenes, drugmakers agreed to supply Bridge medicines at a net price of about $245 a month — but you still pay just $50. That gap is covered for you.
The $50 doesn’t count toward your out-of-pocket cap.
Medicare’s yearly limit on what you pay for covered drugs is $2,100 in 2026 and $2,400 in 2027. Because the Bridge sits outside normal Part D, your Bridge spending doesn’t count toward that cap.
Extra Help can’t be applied.
The low-income drug subsidy doesn’t apply to Bridge medicine. The $50 is $50.
Manufacturer coupons and discount cards can’t be stacked.
A Bridge claim is its own billing route. Savings cards don’t apply.
It ends December 31, 2027.
Build your plan around that date. Watch for news in late 2027 about what comes next.
More on costs: Medicare GLP-1 Bridge $50 copay guide → · True out-of-pocket costs on the Bridge →
How to get it: a step-by-step you can hand to your doctor and pharmacy
Step 1 — At your doctor’s office
Prior authorization (PA) means your doctor gets approval before the pharmacy fills the medicine. For the Bridge, your doctor sends that request to a single CMS central processor (CMS chose SS&C Health/RelayHealth to run it) — not to your regular drug plan. Any licensed clinician can submit it.
What to say to your doctor:
“I’d like to use the Medicare GLP-1 Bridge for the Zepbound KwikPen starting July 1, 2026. Can you confirm my BMI from when I started GLP-1 treatment and any qualifying condition, write the prescription for a KwikPen (not a vial or single-dose pen), and send the prior authorization to the CMS central processor?”
Step 2 — At the pharmacy
Once approved, the pharmacy fills your KwikPen and bills it through the Bridge’s own billing route. Pharmacies don’t have to sign up in advance — they just need to send the claim the right way. Show your pharmacist this card:
💊 Medicare GLP-1 Bridge pharmacy billing card
| Field | Value |
|---|---|
| Plan name | GLP1Bridge |
| BIN | 028918 |
| PCN | MEDDGLP1BR |
| Processor | SS&C Health (claims via RelayHealth) |
| Starts | July 1, 2026 |
| Help desk | 844-673-0910 |
What to say to your pharmacist:
“This is a Medicare GLP-1 Bridge prescription, not a regular Part D claim. It uses BIN 028918 and PCN MEDDGLP1BR through SS&C Health. Can you check your billing instructions for it?”
Doctor script + pharmacy card, combined into one printable. No sign-up.
Already taking Zepbound? Here’s what to do
You’re on Zepbound and your BMI dropped.
Good — that means it’s working. Don’t count yourself out. Ask your prescriber to document the BMI you had when treatment started, plus any qualifying condition you had then.
You currently use Zepbound vials or single-dose pens.
Those forms aren’t covered by the Bridge. Ask your prescriber whether switching to the KwikPen makes sense for you. Don’t try to move medicine between devices or change your dose on your own — let your clinician guide it.
You’re nervous about the KwikPen because of arthritis, hand strength, or injection worries.
That’s a fair concern, not a silly one. Ask your doctor or pharmacist to show you how the pen works before you commit. It’s designed to be simple, but it’s smart to try it with someone watching.
Quick records to pull together before July 1:
- ·Starting BMI (height + weight when you began GLP-1 treatment)
- ·Your diagnosis or qualifying condition
- ·Your current Zepbound form (KwikPen, vial, or single-dose pen)
- ·Your current dose
- ·Your prescriber’s and pharmacy’s contact info
Related: Does the Medicare GLP-1 Bridge cover Zepbound vials? →
What if your Zepbound is for sleep apnea, not weight loss?
Zepbound for weight loss
→ The Medicare GLP-1 Bridge ($50/month, if eligible)
Zepbound for moderate-to-severe sleep apnea
→ Your regular Part D plan (plan’s normal rules and approval)
A note on diabetes
Zepbound’s sister drug Mounjaro contains the same active ingredient (tirzepatide) but is FDA-approved for type 2 diabetes — and Medicare drug plans can cover Mounjaro for diabetes. If you have diabetes, that’s often a simpler covered path, though your actual cost depends on your plan.
Ask your prescriber: “Is this being sent through the Bridge for weight loss, or through my regular Part D plan for sleep apnea?” Getting that right up front can save you a denial and a re-do.
What if you don’t qualify for the Bridge?
If you have Sleep apnea or diabetes →
Use the regular Part D path (Zepbound for sleep apnea, or Mounjaro for diabetes). A covered medical condition is often the most reliable covered route.
If you have You have Medicaid →
Check whether your state covers weight-loss GLP-1s. As of January 2026, about 13 state Medicaid programs covered GLP-1s for obesity (fee-for-service), and states can join the Medicaid side of the BALANCE Model. Rules vary a lot by state — call your state Medicaid office for the current answer.
If you’re on commercial insurance or paying cash:
Brand-name Zepbound KwikPen is available through several routes, including LillyDirect and telehealth providers. Ro (sponsored affiliate link, opens in a new tab) carries FDA-approved Zepbound KwikPen: the medication is $299 for the first month, then $399–$449/month at higher doses, billed separately from Ro’s membership ($39 first month, then as low as $74/month on an annual plan, or $149/month otherwise). Ro also runs your commercial insurance for free and handles prior-authorization paperwork.
Disclosure: The RX Index may earn a commission if you start with a partner like Ro, at no extra cost to you. It never changes who we recommend, and nothing about the Bridge requires a telehealth provider.
GLP-1 cost without insurance — cash-pay comparison →
Is the Zepbound KwikPen safe? What to ask your doctor
Boxed warning (FDA’s most serious warning).
In animal studies, the active ingredient caused thyroid tumors. It’s unknown whether this happens in people. Zepbound should not be used if you or a family member has had medullary thyroid carcinoma (MTC), or a condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
It’s prescription-only.
Meant to be used with a reduced-calorie diet and more physical activity. Never share your KwikPen with anyone, even with a new needle.
Talk to your clinician about these precautions.
Pancreatitis (pancreas inflammation) · gallbladder problems · severe stomach or digestive problems · dehydration and possible kidney injury (often from nausea and vomiting) · low blood sugar if you also take insulin or a sulfonylurea · a history of diabetic eye disease · serious allergic reactions · risk of food coming back up during surgery (these drugs slow stomach emptying — tell your care team before any procedure).
Common side effects.
Nausea, diarrhea, vomiting, constipation, stomach pain, indigestion, injection-site reactions, fatigue, burping, hair loss, and acid reflux — most often when starting or increasing the dose.
Good questions to ask your doctor: Am I a good candidate given my history? What side effects should I plan for? What’s my target dose? And what happens to my weight if the program ends in 2027 and I stop?
How we verified this Zepbound KwikPen Bridge guide
| What we checked | Primary source | Verified |
|---|---|---|
| Bridge dates (Jul 1, 2026 – Dec 31, 2027) | CMS / KFF | May 28, 2026 |
| $50 copay, flat at every dose | CMS / KFF | May 28, 2026 |
| KwikPen included; vials/single-dose pens excluded | CMS | May 28, 2026 |
| Three eligibility tiers (BMI + conditions) | CMS Bridge rules | May 28, 2026 |
| Which Medicare plan types qualify | CMS | May 28, 2026 |
| Outside Part D; doesn’t count toward cap; no Extra Help/coupons | CMS / KFF | May 28, 2026 |
| ~$245 net program price | CMS FAQ | May 28, 2026 |
| Pharmacy billing route (BIN 028918 / PCN MEDDGLP1BR) | CMS GLP-1 Bridge payer sheet | May 28, 2026 |
| KwikPen NDC codes by strength | LillyDirect / DailyMed | May 28, 2026 |
| Zepbound uses, warnings, KwikPen facts | FDA / Lilly label | May 28, 2026 |
| Self-pay Zepbound KwikPen pricing | Lilly / LillyDirect | May 28, 2026 |
| Ro pricing + government-insurance limitation | Ro (ro.co) | May 28, 2026 |
Frequently asked questions about the Zepbound KwikPen and the CMS BALANCE Bridge
Is the Zepbound KwikPen covered by Medicare in 2026?
Eligible Medicare Part D members can get the Zepbound KwikPen for $50 a month through the Medicare GLP-1 Bridge starting July 1, 2026. It is a temporary program running through December 31, 2027, and it covers the KwikPen only — not vials or single-dose pens.
Does the CMS BALANCE Model cover Zepbound vials?
No. For the Bridge, CMS includes the Zepbound KwikPen and excludes the single-dose vials and single-dose pens. Vial users should ask their prescriber about switching to the KwikPen before assuming they can get the $50 price.
Is the Zepbound KwikPen copay really $50?
Yes, the Bridge copay is $50 a month and stays $50 at every dose. The main catch is that the Bridge runs outside normal Medicare drug coverage, so the $50 does not count toward your yearly out-of-pocket limit, and Extra Help and coupons cannot be applied.
Who qualifies for the Zepbound KwikPen Bridge?
You need a Medicare drug plan and must meet one of three tiers, based on your BMI when GLP-1 treatment started: a BMI of 35 or higher on its own; a BMI of 30 or higher with HFpEF, uncontrolled high blood pressure on two medications, or kidney disease stage 3a or worse; or a BMI of 27 or higher with prediabetes, a past heart attack, a past stroke, or symptomatic peripheral artery disease.
Does Medicare Advantage qualify?
Some Medicare Advantage drug plans (MA-PD plans — including HMO, HMO-POS, and PPO plans) can qualify, but not every plan type does. Original Medicare with no drug plan is not enough, and a few special plan types are excluded unless you also have a standalone Part D plan.
Can my own doctor submit the prior authorization?
Yes. Any licensed clinician can send the Bridge prior authorization to the CMS central processor, as long as they are not blocked by CMS. No special enrollment is required.
What if my Zepbound is for sleep apnea?
If Zepbound is prescribed for moderate-to-severe obstructive sleep apnea in an adult with obesity, it goes through your regular Part D plan, not the Bridge. Your plan can still require prior authorization and normal cost-sharing, so be clear with your doctor about which path applies.
Can I use Ro or another telehealth service if I’m on Medicare?
No. Ro states that it cannot coordinate GLP-1 coverage for government insurance plans like Medicare, Medicaid, or TRICARE, and Medicaid members generally cannot use it at all. If you’re on Medicare or Medicaid, use the Bridge or your Part D plan. Cash-pay telehealth is an option only for people on commercial insurance or paying out of pocket.
Do compounded GLP-1s count for the Bridge?
No. The Bridge covers FDA-approved Zepbound KwikPen. Compounded tirzepatide — mixed by a pharmacy rather than made by the brand manufacturer — is not FDA-approved Zepbound and is not part of the Bridge.
What happens after December 31, 2027?
The Bridge is scheduled to end then. According to KFF, there is no clear path for ongoing Medicare coverage of weight-loss-only GLP-1 use after that unless the larger BALANCE Model launches for Medicare drug plans. Treat the Bridge as an 18-month window and watch for news in late 2027.
Still not sure which GLP-1 program is right for you?
The Bridge, regular Part D, Medicaid, and cash-pay all play by different rules. Our free 60-second quiz will show you your exact route — including the next step for your situation.
Take the free 60-second quiz →Related guides
- Medicare GLP-1 Bridge eligibility: do you qualify?
- Medicare GLP-1 Bridge $50 copay — full guide
- True out-of-pocket costs on the Medicare GLP-1 Bridge
- Bridge and the Part D coverage gap
- Does the Bridge cover Zepbound vials?
- Does the Bridge cover the Wegovy pill?
- Why the CMS BALANCE Model was delayed
- CMS BALANCE Model GLP-1 overview
- CMS BALANCE Model Foundayo — $50 Medicare path
- GLP-1 cost without insurance: cash-pay comparison
Sources
- ·CMS — Medicare GLP-1 Bridge (dates, drug list, $50 copay, KwikPen-only rule, eligibility tiers, plan types, PA process, pharmacy billing route, BIN/PCN)
- ·CMS — GLP-1 Bridge payer sheet (BIN 028918, PCN MEDDGLP1BR, SS&C Health, March 16, 2026)
- ·KFF — What to Know About the CMS BALANCE Model and the GLP-1 Bridge (BALANCE delay, no clear post-2027 path, 56% affordability finding)
- ·FDA / Lilly — Zepbound (tirzepatide) prescribing information: label, boxed warning, uses, KwikPen facts
- ·LillyDirect / DailyMed — Zepbound KwikPen NDC codes by strength; self-pay pricing
- ·Ro (ro.co) — Zepbound KwikPen cash pricing; government-insurance limitation statement
By The RX Index Editorial Team — a pricing intelligence and comparison resource for GLP-1 telehealth providers. Published May 28, 2026. This article is for general information and is not medical advice. Coverage, eligibility, and prices depend on your plan, your diagnosis, your prescriber, and your pharmacy, and can change — talk with a licensed clinician and confirm current details with your plan before making decisions. Some links are affiliate links — we may earn a commission at no extra cost to you.